Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | AACR 2023 highlights in PI3Kα and FGFR inhibition

Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of her highlights from the 2023 American Association for Cancer Research (AACR) Annual Meeting 2023, including findings from a Phase I trial (NCT05216432) of RLY-2608, a novel PI3Kα inhibitor, in patients with solid tumors. Dr Schram additionally highlights findings from FIGHT-207 trial (NCT03822117) of pemigatinib in FGFR-mutant tumors, as well as novel advances in ATR inhibitors. This interview took place at the AACR Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.